CoreWeave's Core Scientific Bid: A Data Center Power Play in the AI Era

The sudden 33% surge in Core Scientific's (CORZ) stock price to $16.44 on June 26, 2025, has reignited speculation about its potential acquisition by CoreWeave (CRWV), a leading AI infrastructure provider. The spike, driven by reports of advanced buyout talks, reflects a broader shift in the data center sector: the scramble to secure GPU-driven compute capacity for artificial intelligence. For investors, the deal—if finalized—could reshape the landscape of high-performance computing (HPC), but it also raises critical questions about valuation, execution risks, and the sustainability of current momentum.

The Strategic Imperative: Why CoreWeave Wants Core Scientific

CoreWeave's interest is clear: Core Scientific owns 724 MW of immersion-cooled GPU capacity, a critical asset for training large-scale AI models. These facilities, originally built for cryptocurrency mining, now form the backbone of Core Scientific's pivot to colocation services for HPC workloads. CoreWeave, which serves clients like Microsoft and OpenAI, faces skyrocketing demand for its cloud platform. By acquiring Core Scientific, it could avoid the costly and time-consuming process of building its own infrastructure, instead leveraging an existing network of data centers across the U.S. and Canada.

The $10.2 billion, 12-year revenue commitment from CoreWeave in 2024—secured through contracts for 590 MW of capacity—already binds the two companies. Closing the acquisition would lock in this relationship, ensuring CoreWeave's dominance in a sector where GPU shortages have become a bottleneck.

Valuation: A Risky Premium for Strategic Assets

Core Scientific's current $3.7 billion market cap represents a dramatic upgrade from the $1 billion valuation in CoreWeave's rejected 2024 bid. Analysts speculate that the new offer could value shares at $25–$30, a 50–80% premium to recent levels. This reflects Core Scientific's transition from a distressed bitcoin miner to an AI infrastructure play, but it also raises concerns about overvaluation.

Core Scientific's Q1 2025 net income of $580 million relied heavily on its shift to colocation services, which now account for 80% of revenue. However, its Bitcoin mining revenue dropped by $82.8 million, underscoring dependency on AI contracts. If CoreWeave's clients—like OpenAI—fail to deliver the expected revenue streams, Core Scientific's financials could falter.

Risks: Overbought, Overleveraged, and Overdue

• Execution Challenges: Delivering the 590 MW by early 2026 is a tight deadline. Delays could void the $10.2 billion revenue guarantee and weaken both companies' financial health.
• Debt and Dilution: CoreWeave already carries $8 billion in debt. A stock-based deal could dilute existing shareholders, while a cash offer risks further debt accumulation.
• Market Sentiment: Core Scientific's 14-day Relative Strength Index (RSI) has entered overbought territory, signaling a potential correction.

Investment Implications: A High-Risk, High-Reward Crossroads

For traders, the near-term opportunity hinges on speculation about the deal's terms. A $25–$30 target would justify the current rally, but a breakdown below $14—Core Scientific's 2024 lows—could erase gains. Technical traders might consider a “buy the dip” strategy with a tight stop-loss, while long-term investors should wait for confirmation of the acquisition.

The broader sector context is equally important. The AI infrastructure boom is fueling consolidation: competitors like Equinix and Digital Realty are expanding, while startups like CoreWeave aim to corner niche markets. A Core Scientific deal would position CoreWeave as a North American HPC powerhouse, but its success depends on execution.

Conclusion: Proceed with Caution, but Keep an Eye on Synergies

The CoreWeave-Core Scientific deal embodies the data center sector's evolution: from commodity cloud storage to specialized AI compute. While the strategic logic is sound, investors must weigh the risks of overvaluation, execution failure, and regulatory scrutiny (e.g., antitrust concerns).

For now, the stock surge reflects optimism about the synergy. Traders may profit from short-term momentum, but long-term holders should demand clarity on the deal's terms and Core Scientific's ability to meet its infrastructure deadlines. The AI infrastructure race is only beginning—this acquisition could be its first major milestone.

Greg Ip is a pseudonym for the author of this analysis.